Table 1

General characteristics

	PedSjD n=19		Diagnostic adSjD n=32		PedSjD versus diagnostic adSjD P value	Trial adSjD n=42		PedSjD versus trial adSjD P value
Gender, female, n (%)	15 (78.9)		31 (96.9)		0.58	38 (90.5)		0.24
Age at start symptoms, years*	9 (9–12)		45 (30–58)		*0.001*	44 (30–56)		*0.001*
Age at biopsy, years*	14 (10–17)		52 (46–63)		*0.001*	51 (39–61)		*0.001*
Duration of symptoms at moment of biopsy, years*	3 (2–5)		5 (3–13)		*0.024*	4 (2–8)		0.07
Fulfilment of ACR/EULAR criteria, n (%)	16 (84)		32 (100)		*0.022*	40 (95)		0.15
ESSDAI total score, range*	5 (3–11)		4 (2–12)		0.54	11 (8–16)		*0.001*
ESSDAI score glandular, range domain*	2 (2–4)		0 (0–2)		*0.001*	1 (1–2)		*0.001*
ESSDAI glandular domain positive, n (%)	18 (94.7)		12 (37.5)		*<0.001*	33 (78.6)		*0.117*
Ultrasound
Hocevar score total, range*	23 (13–29)†		16 (9–24)†		0.28	16 (11–29)‡		0.33
Hocevar score parotis, range*	10 (8–16)†		8 (4–12)†		0.24	8 (4–14)‡		0.38
Hocevar score percentage parotis/total score*	52 (48–55)†		52 (36–57)†		0.82	50 (38–58)‡		0.78
OMERACT score total*	8 (5–10)†		6 (1.5–8)†		0.74	6 (3–11)‡		0.35
Salivary flow rates
UWS value, mL/min*	0.18 (0.05–0.55)§		0.09 (0.03–0.19)		*0.041*	0.10 (0.02–0.18)		*0.046*
UWS <0.1 mL/min, n (%)	7 (38.9)§		19 (59.4)		0.16	23 (54.8)		0.26
SWS value, mL/min*	0.4 (0.22–0.59)§		0.65 (0.34–0.94)		0.98	0.26 (0.11–0.45)		*0.033*
Medication use, n (%)	Current	History	Current	History		Current	History
Hydroxychloroquine	5 (26)	7 (37)	3 (9)	12 (38)		1 (2)	11 (26)
tDMARD	1 (5)	0 (0)	3 (9)	8 (25)		0 (0)	7 (17)
Corticosteroids	1 (5)	2 (11)	3 (9)	1 (3)		0 (0)	6 (14)

Significant p values are italicised and bold.
*Data are reported as median (IQR) or n (%).
§Missing data: 0–5; †Missing data: 6–10; ‡Missing data: 11–15
ACR/EULAR, American College of Rheumatology/EULAR; adSjD, adult-onset Sjögren’s disease; ESSDAI, EULAR Sjogren’s Syndrome Disease Activity Index; OMERACT score, Outcome Measures in Rheumatolgy ultrasound score; PedSjD, paediatric-onset Sjögren’s disease; SWS, stimulated whole saliva; tDMARD, traditional disease-modifying antirheumatic drug; UWS, unstimulated whole saliva.